Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)

被引：45

作者：

Bellini, Angela ^{[1
,2
,3
]}

Poetschger, Ulrike ^{[4
,5
]}

Bernard, Virginie ^{[6
]}

Lapouble, Eve ^{[7
]}

Baulande, Sylvain ^{[6
]}

Ambros, Peter F. ^{[5
]}

Auger, Nathalie ^{[8
,9
]}

Beiske, Klaus ^{[10
,11
]}

Bernkopf, Marie ^{[5
]}

Betts, David R. ^{[12
]}

Bhalshankar, Jaydutt ^{[1
,2
,3
]}

Bown, Nick ^{[13
]}

de Preter, Katleen ^{[14
]}

Clement, Nathalie ^{[1
,2
,3
]}

Combaret, Valerie ^{[15
]}

de Mora, Jaime Font ^{[16
]}

George, Sally L. ^{[17
]}

Jimenez, Irene ^{[1
,2
,3
]}

Jeison, Marta ^{[18
]}

Marques, Barbara ^{[19
]}

Martinsson, Tommy ^{[20
]}

Mazzocco, Katia ^{[21
]}

Morini, Martina ^{[22
]}

Muehlethaler-Mottet, Annick ^{[23
,24
]}

Noguera, Rosa ^{[25
]}

Pierron, Gaelle ^{[7
]}

Rossing, Maria ^{[26
]}

Taschner-Mandl, Sabine ^{[5
]}

Van Roy, Nadine ^{[14
]}

Vicha, Ales ^{[27
,28
]}

Chesler, Louis ^{[29
]}

Balwierz, Walentyna ^{[30
]}

Castel, Victoria ^{[31
]}

Elliott, Martin ^{[32
]}

Kogner, Per ^{[33
]}

Laureys, Genevieve ^{[34
]}

Luksch, Roberto ^{[35
]}

Malis, Josef ^{[27
,28
]}

Popovic-Beck, Maja ^{[24
,36
]}

Ash, Shifra ^{[37
]}

Delattre, Olivier ^{[2
,3
,6
]}

Valteau-Couanet, Dominique ^{[38
]}

Tweddle, Deborah A. ^{[39
]}

Ladenstein, Ruth ^{[40
,41
]}

Schleiermacher, Gudrun ^{[1
,2
,3
]}

机构：

[1] Inst Curie, Equipe SiR RTOP Rech Translat Oncol Pediat, Paris, France

[2] Inst Curie, Lab Genet & Biol Canc, INSERM U830, Paris, France

[3] Inst Curie, SIREDO Care Innovat & Res Children Adolescents &, Paris, France

[4] Dept Studies & Stat & Integrated Res, Vienna, Austria

[5] St Anna Childrens Canc Res Inst, Vienna, Austria

[6] Inst Curie, Inst Curie Genom Excellence ICGex Platform, Res Ctr, Paris, France

[7] Inst Curie, Hosp Grp, Serv Genet, Unite Genet Somat, Paris, France

[8] Serv Genet Tumeurs, Villejuif, France

[9] Inst Gustave Roussy, Villejuif, France

[10] Univ Oslo, Oslo Univ Hosp, Dept Pathol, Oslo, Norway

[11] Univ Oslo, Med Fac, Oslo, Norway

[12] Childrens Hlth Ireland Crumlin, Dept Clin Genet, Dublin, Ireland

[13] Newcastle upon Tyne Hosp NHS Fdn Trust, Northern Genet Serv, Newcastle Upon Tyne, Tyne & Wear, England

[14] Univ Ghent, Ghent, Belgium

[15] Ctr Leon Berard, Translat Res Lab, Lyon, France

[16] Inst Invest Sanitaria La Fe, Valencia, Spain

[17] Inst Canc Res, Div Clin Studies, London, England

[18] Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Tel Aviv, Israel

[19] Inst Nacl Saude Doutor Ricardo Jorge, Dept Genet Humana, Lisbon, Portugal

[20] Sahlgrens Univ Hosp, Gothenburg, Sweden

[21] IRCCS Ist Giannina Gaslini, Dept Pathol, Genoa, Italy

[22] IRCCS Ist Giannina Gaslini, Lab Mol Biol, Genoa, Italy

[23] Lausanne Univ Hosp, Pediat Hematol Oncol Res Lab, Lausanne, Switzerland

[24] Univ Lausanne, Lausanne, Switzerland

[25] Univ Valencia, Med Sch, Dept Pathol, Incl Hlth Res Inst CIBERONC, Madrid, Spain

[26] Copenhagen Univ Hosp, Rigshosp, Ctr Genom Med, Copenhagen, Denmark

[27] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic

[28] Univ Hosp Motol, Prague, Czech Republic

[29] Inst Canc Res, Div Clin Studies, Paediat Tumour Biol, Sutton, Surrey, England

[30] Jagiellonian Univ Med Coll, Inst Pediat, Dept Pediat Oncol & Hematol, Krakow, Poland

[31] Hlth Res Inst La Fe, Clin & Translat Oncol Res Grp, Valencia, Spain

[32] Leeds Childrens Hosp, Leeds Gen Infirm, Leeds, W Yorkshire, England

[33] Karolinska Univ Hosp, Stockholm, Sweden

[34] Ghent Univ Hosp, Princess Elisabeth Childrens Hosp, Dept Paediat Haematol & Oncol, Ghent, Belgium

[35] Ist Nazl Tumori, Fdn IRCCS, Paediat Oncol, Milan, Italy

[36] Lausanne Univ Hosp, Pediat Hematol Oncol Unit, Lausanne, Switzerland

[37] Ruth Rappaport Childrens Hosp, Rambam Hlth Care Campus, Haifa, Israel

[38] Gustave Roussy, Dept Oncol Pediat, Villejuif, France

[39] Newcastle Univ, Wolfson Childhood Canc Res Ctr, Newcastle Ctr Canc, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[40] St Anna Childrens Hosp, St Anna Childrens Canc Res Inst, Dept Studies & Stat & Integrated Res, Vienna, Austria

[41] Med Univ Vienna, Dept Paediat, Vienna, Austria

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 30期

关键词：

SEGMENTAL CHROMOSOMAL ALTERATIONS; ACTIVATING MUTATIONS; PEDIATRIC-PATIENTS; CRIZOTINIB; REVEALS; RELAPSE; KINASE; REARRANGEMENTS; HETEROGENEITY; CHEMOTHERAPY;

D O I：

10.1200/JCO.21.00086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. MATERIALS AND METHODS Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571). RESULTS Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with a significantly poorer overall survival (OS) (5-year OS: ALKa [n = 41] 28% [95% CI, 15 to 421; no-ALKa [n = 860] 51% [95% CI, 47 to 54], [P < .001]), particularly in cases with metastatic disease. ALK mutations (ALKm) were detected at a clonal level (> 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALKm and MNA (P< .001). Among 571 cases with known ALKa and ALKm status, a statistically significant difference in OS was observed between cases with ALKa or clonal ALKm versus subclonal ALKm or no ALK alterations (5-year OS: ALKa En = 19], 26% [95% CI, 10 to 47], clonal ALKm En = 65] 33% [95% CI, 21 to 44], subclonal ALKm (n = 22) 48% [95% CI, 26 to 67], and no alteration En = 465], 51% [95% CI, 46 to 55], respectively; P = .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P < .001), ALKa (HR, 2.38; P = .004), and clonal ALKm (HR, 1.77; P = .001) were independent predictors of poor outcome. CONCLUSION Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations. (C) 2021 by American Society of Clinical Oncology

引用

页码：3377 / +

页数：28

共 50 条

[31] Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
Veal, G. J.
Nguyen, L.
Paci, A.
Riggi, M.
Amiel, M.
Valteau-Couanet, D.
Brock, P.
Ladenstein, R.
Vassal, G.
EUROPEAN JOURNAL OF CANCER, 2012, 48 (16) : 3063 - 3072
[32] Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).
Ladenstein, Ruth
Poetschger, Ulrike
Gray, Juliet
Valteau-Couanet, Dominique
Luksch, Roberto
Castel, Victoria
Yaniv, Isaac
Laureys, Genevieve
Elliott, Martin
Michon, Jean Marie
Owens, Cormac
Trahair, Toby
Chan, Godfrey Chi Fung
Ruud, Ellen
Schroeder, Henrik
Popovic, Maja Beck
Glogova, Evgenia
Schreier, Guenter
Loibner, Hans
Lode, Holger N.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] The Randomised Induction for High-Risk Neuroblastoma Comparing COJEC and N5-MSKCC Regimens. Early Results from the HR-NBL1.5/SIOPEN Trial
Ladenstein, R.
Poetschger, U.
Valteau-Couanet, D.
Castel, V.
Elliott, M.
Ash, S.
Chan, G.
Laureys, G.
Beck-Popovic, M.
Vettenranta, K.
Balwierz, W.
Schroeder, H.
Owens, C.
Cesen, M.
Papadakis, V.
Trahair, T.
Luksch, R.
Schleiermacher, G.
Ambros, P.
Garaventa, A.
PEDIATRIC BLOOD & CANCER, 2018, 65 : S11 - S11
[34] The randomised induction for high-risk neuroblastoma comparing COJEC and N5-MSKCC regimens: Early results from the HR-NBL1.5/SIOPEN trial.
Garaventa, Alberto
Poetschger, Ulrike
Valteau-Couanet, Dominique
Castel, Victoria
Elliott, Martin
Ash, Shifra
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[35] Early Results from the HR-NBL1/SIOPEN Trial Randomizing Dose-Reduced Subcutaneous Interleukin2 (SCIL2) with Dinutuximab Beta (DB) Long-Term Infusion (LTI) in High-Risk Neuroblastoma Patients
Ladenstein, R.
Poetschger, U.
Valteau-Couanet, D.
Gray, J.
Luksch, R.
Balwierz, W.
Castel, V.
Ash, S.
Beck-Popovic, M.
Laureys, G.
Chan, G. Chi Fung
Ruud, E.
Vettenranta, K.
Owens, C.
Schroeder, H.
Loibner, H.
Ambros, P.
Sarnacki, S.
Boterberg, T.
Lode, H.
PEDIATRIC BLOOD & CANCER, 2019, 66 : S31 - S32
[36] Success of the HR-NBL/SIOPEN local control trial strategy in high risk neuroblastoma patients undergoing high dose therapy with peripheral stem cell transplantation
Ladenstein, Ruth
Poetscher, Ulrike
Luksch, Roberto
Castel, Victoria
Yaniv, Isaac
Papadakis, Vassilios
Laureys, Genevieve
Malis, Josef
Balwierz, Walentyna
Ruud, Ellen
Kogner, Per
Schroeder, Henrik
de Lacerda, Ana Forjaz
Beck-Popovic, Maja
Bician, Pavel
Garami, Miklos
Trahair, Toby
Canete, Adela
Ambros, Peter
Holmes, Keith
Garaventa, Alberto
Michon, Jean
Pearson, Andrew
Valteau-Couanet, Dominique
Gaze, Mark
Botterberg, Tom
BONE MARROW TRANSPLANTATION, 2018, 53 : 128 - 129
[37] Experience of running a European randomised Megatherapy Trial (HR-NBL-1/ESIOP) for high-rrisk neuroblastoma within a Research Environment: the SIOPEN-R-NET project
Ladenstein, R
Poetschger, U
Schreier, G
Gadner, H
De Bernardi, B
Castel, V
Foot, A
Michon, J
Pearson, A
BONE MARROW TRANSPLANTATION, 2005, 35 : S84 - S85
[38] Results of a Quality Assurance Review of External Beam Radiation Therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: A SIOPEN Study
Gaze, Mark N.
Boterberg, Tom
Dieckmann, Karin
Hoermann, Marcus
Gains, Jennifer E.
Sullivan, Kevin P.
Ladenstein, Ruth
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (01): : 170 - 174
[39] Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data.
Bagatell, Rochelle
Fisher, Brian
Self, Alix Eden
Huang, Yuan-Shung
Li, Yimei
Desai, Ami Vijay
London, Wendy B.
Van Ryn, Collin
Park, Julie R.
Richardson, Troy
Hall, Matt
Aplenc, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial
Moreno, L.
Moroz, V.
Owens, C.
Valteau-Couanet, D.
Gambart, M.
Castel, V.
van Eijkelenburg, N.
Castellano, A.
Nysom, K.
Gerber, N.
Laureys, G.
Ladenstein, R.
Thebaud, E.
Murphy, D.
Morland, B.
Vaidya, S.
Elliott, M.
Pearson, A. D.
Wheatley, K.
ANNALS OF ONCOLOGY, 2019, 30 : 901 - 901

← 1 2 3 4 5 →